Venclyxto/Venclexta combination shows sustained PFS in CLL after four years off treatment

Rucaparib maintenance therapy demonstrates PFS benefit for HRD-negative and HRD-positive ovarian cancer

First-line rucaparib maintenance treatment provided a progression-free survival benefit vs placebo in newly diagnosed, advanced, high-grade ovarian cancer after front-line platinum-based chemotherapy.

June 27, 2025

Vol.51 No.25

Podcast

In the Headlines: What if curing diseases was treated like a business?

A 25-year old idea, a concept named “the American Centers for Cures,” proposed by Lou Weisbach, a former CEO of a Fortune 500 company and a political insider, aims to shift the paradigm of research funding.

June 25, 2025

Vol.51 No.24

As Trump decimates NIH funding, a daring proposal to issue $750 billion in bonds for medical cures garners attention

As biomedical research at NIH faces an existential threat from the Trump administration, an entrepreneur is winning over allies for what he describes as a “simple idea” that could introduce a massive new infusion of money for innovation in medicine.

FDA to issue “national priority vouchers” to companies supporting U.S. interests

A new FDA voucher program will aim to accelerate review time for applications that are deemed to be advancing U.S. “national priorities.”

June 20, 2025

Vol.51 No.24

By Claire Marie Porter

Cancer Policy

FDA halts new clinical trials that export Americans’ cells to foreign labs in hostile countries

FDA has announced that the agency will begin immediately reviewing all new clinical trials that include shipping American citizens’ living cells to “China and other hostile countries for genetic engineering and subsequent infusion” back into American patients.

June 20, 2025

Vol.51 No.24

By Claire Marie Porter

Clinical Roundup

Study of retifanlimab in squamous cell carcinoma meets primary endpoint of PFS

Primary results from the phase III POD1UM-303/InterAACT 2 trial of retifanlimab (Zynyz), a humanized monoclonal antibody targeting programmed death receptor-1, in combination with carboplatin and paclitaxel (platinum-based chemotherapy) in adult patients with inoperable locally recurrent or metastatic squamous cell carcinoma of the anal cancer who have not been previously treated with systemic chemotherapy, were published in The Lancet.

June 20, 2025

Vol.51 No.24

Venclyxto/Venclexta combination shows sustained PFS in CLL after four years off treatment

YOU MAY BE INTERESTED IN

Rucaparib maintenance therapy demonstrates PFS benefit for HRD-negative and HRD-positive ovarian cancer

In the Headlines: What if curing diseases was treated like a business?

As Trump decimates NIH funding, a daring proposal to issue $750 billion in bonds for medical cures garners attention

FDA to issue “national priority vouchers” to companies supporting U.S. interests

FDA halts new clinical trials that export Americans’ cells to foreign labs in hostile countries

Study of retifanlimab in squamous cell carcinoma meets primary endpoint of PFS

Renew today!

Subscriber content

Never miss an issue!

Login